Etcembly Ltd

✨ Happy Holidays from Etcembly! 🎄🎉 As the year comes to a close, we want to take a moment to reflect on what has been an incredible 2024. This year’s highlights include: - The launch of our Long Term Survivor Study, including a new partnership with the University of Surrey, helping us uncover the next generation of cancer targets in the immune repertoires of survivors. - Continued breakthroughs with our EMLy™ AI platform, driving TCR and antibody discovery, optimization and engineering to new heights. - Strengthened partnerships with leaders across tech, biotech and academia to advance immunotherapy. 🚀 But this is just the beginning! 2025 is shaping up to be an even more exciting year, with some big announcements and developments already in the works. Stay tuned—you won’t want to miss what’s coming next. From all of us at Etcembly, thank you for being part of our journey. Wishing you a joyful holiday season and a bright start to the new year! #biotech #techbio #AI #immunotherapy #happyholidays #happynewyear

To fully unlock the potential of immunotherapy for cancer patients, we don’t need just better treatments - we need better targets. Since the approval of the first immune checkpoint inhibitor in 2011, immunotherapy has transformed oncology. We’ve seen durable responses in some patients with advanced disease, which are tantamount to a cure. But these drugs don’t work for all, and they can have serious or even fatal side effects. In this new article in Drug Target Review our CEO Michelle Teng explains how the new wave of AI computing platforms and large language models (LLMs) are set to transform our understanding of how antibodies and TCRs interact with antigens, shedding light on new targets and accelerating the development of life-changing immunotherapies. Leading the pack is our own LLM-based generative AI engine, EMLy™, which already outperforms AlphaFold3 in predicting the structure of the TCR:HLA interface from the protein sequence, and is constantly improving as we feed in more data from our Long Term Survivor Study. We’re now working to open these tools and capabilities to the research community, harnessing intuitive Co-pilot technology to enable real-time interrogation and manipulation of antibodies and TCRs - watch this space! Read the full article here: https://lnkd.in/e9bCJUvA #AI #biotech #techbio #immunotherapy #LLM

Who's excited for this year's Antibody Engineering and Therapeutics conference #AET2024? Our Head of Pipeline, Alfred Lim, will be attending the event in San Diego from December 15-18. He’s eager to dive into discussions about the latest advances in antibody engineering, machine learning for drug discovery, and cutting-edge therapeutic approaches like bi-specifics, multi-specifics, and T-cell therapies. If you’ll be there too it’s the perfect chance to connect! Reach out to us on LinkedIn to set up a meeting and learn more about our groundbreaking EMLy discovery engine and pipeline of TCR-based immune engagers. Let’s advance the future of immunotherapy together! 📅 December 15-18 📍 San Diego, Marriott Marquis Can’t make it? Drop us a line to learn more: https://lnkd.in/e7WgHj-B #antibodyeng #immunotherapy #AI #TCRtherapies #bispecifics #machinelearning

At Etcembly, we’re transforming in silico protein engineering with DoRIAT (Docking Run Interpretation and Annotation Tool). DoRIAT accurately evaluates TCR-pHLA binding, which is essential for advancing T-cell-based therapies and unlocking breakthroughs in fields like cancer immunotherapy. This is just one of the tools within our EMLy™ AI engine - the most powerful platform for immunotherapy discovery and engineering ever created. For scientists, it’s a powerful tool to accelerate discoveries. For investors, it’s a glimpse into the future of drug development powered by cutting-edge AI. Discover more: https://lnkd.in/e5Ax6dby #ProteinEngineering #Immunotherapy #DrugDiscovery #AI #Biotech #TechBio #TCRs

Researchers at Oxford techbio Etcembly Ltd hope to find new targets for cancer therapies by analysing the immune cells of cancer survivors, as principal scientist Mathew Jones explains https://lnkd.in/eU-93c9r

Thank you to STFC Business & Innovation for showcasing our innovative approach combining computing and immunology to drive forward the development of next-generation immunotherapies. Take a look at their case study to learn more about what we're up to from our base at Harwell Science and Innovation Campus 👇 #DrugDevelopment #Biotech #Immunotherapy #innovation #AI

At Etcembly, we’re revolutionizing TCR engineering to meet the urgent need for effective and scalable immunotherapies. Our AI platform EMLy™ can take TCR sequences and predict stable, affinity-matured variants with optimal yield. 💡 The challenge? Therapeutic TCRs must go beyond high affinity—they also require optimal stability, expression, and developability to succeed as viable medicines. ✨ How we solve it: EMLy combines advanced Large Language Models (LLMs) with sequence- and structure-based engineering to produce TCRs with: ✔️ 5-million-fold binding affinity improvement ✔️ 5X increase in yield ✔️ 4℃ increase in thermal stability With EMLy you can supercharge the stability and developability of your asset. To find out more, visit https://lnkd.in/es4MdpfB

Jacob Hurst, our Chief Technology Officer, presented at the #HKPC GBA International Artificial Intelligence & Robotics Summit 2024 last week! #TechBio, #BiotechInnovation, #AI, #TCRs, #Immunotherapy

Last Friday, our CEO Michelle Teng, had the incredible opportunity to sit down with Ian Khan "The Futurist" for an upcoming episode of The Futurist on Amazon Prime! 🚀 The episode will be airing on March 25, but we couldn’t wait to share a sneak peek from behind the scenes. A big thank you to Ian for the engaging discussion, and to BD for allowing us to film in their cutting-edge labs. 👏 At Etcembly, we are dedicated to revolutionizing immunotherapies using generative AI. We can’t wait for you to watch the episode and learn more about how we’re driving innovation in this exciting field. #TheFuturist #AmazonPrime #Immunotherapy #BiotechInnovation #TechBio #TCRs #AI

At Etcembly, we’re revolutionizing TCR engineering to meet the urgent need for effective and scalable immunotherapies. Our AI platform EMLy™ can take TCR sequences and predict stable, affinity-matured variants with optimal yield. 💡 The challenge? Therapeutic TCRs must go beyond high affinity—they also require optimal stability, expression, and developability to succeed as viable medicines. ✨ How we solve it: EMLy combines advanced Large Language Models (LLMs) with sequence- and structure-based engineering to produce TCRs with: ✔️ 5-million-fold binding affinity improvement ✔️ 5X increase in yield ✔️ 4℃ increase in thermal stability With EMLy you can supercharge the stability and developability of your asset. To find out more, visit https://lnkd.in/es4MdpfB